Severe hypercalcemia can be treated by acute hemodialysis and discontinuing Emulsion Scott (Calcium Phosphate) acetate therapy. More severe hypercalcemia (Ca >12 mg/dL) is associated with confusion, delirium, stupor and coma. Should hypercalcemia develop, reduce the Emulsion Scott (Calcium Phosphate) acetate dosage, or discontinue the treatment, depending on the severity of hypercalcemia Therefore, early in the treatment phase during the dosage adjustment period, monitor serum Emulsion Scott (Calcium Phosphate) levels twice weekly. Avoid the use of Emulsion Scott (Calcium Phosphate) supplements, including Emulsion Scott (Calcium Phosphate) based nonprescription antacids, concurrently with Emulsion Scott (Calcium Phosphate) acetate.Īn overdose of Emulsion Scott (Calcium Phosphate) acetate may lead to progressive hypercalcemia, which may require emergency measures. Patients with end stage renal disease may develop hypercalcemia when treated with Emulsion Scott (Calcium Phosphate), including Emulsion Scott (Calcium Phosphate) acetate. Hypercalcemia may aggravate digitalis toxicity. Severe hypercalcemia may require hemodialysis and discontinuation of Emulsion Scott (Calcium Phosphate) acetate. Treat mild hypercalcemia by reducing or interrupting Emulsion Scott acetate and Vitamin D. Capsule: 667 mg Emulsion Scott (Calcium Phosphate) acetate capsule. (2)Ĭapsule: 667 mg Emulsion Scott (Calcium Phosphate) acetate capsule. Most patients require 3 to 4 capsules with each meal. Titrate the dose every 2 to 3 weeks until acceptable serum phosphorus level is reached. Starting dose is 2 capsules with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. The recommended initial dose of Emulsion Scott (Calcium Phosphate) acetate for the adult dialysis patient is 2 capsules with each meal.

Calcium acetate is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease. Emulsion Scott (Calcium Phosphate) acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).

Emulsion scott